Trial watch

References

• Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ 2007; 14:1237 - 43; http://dx.doi.org/10.1038/sj.cdd.4402148; PMID: 17431418
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19:107 - 20; http://dx.doi.org/10.1038/cdd.2011.96; PMID: 21760595
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16:3 - 11; http://dx.doi.org/10.1038/cdd.2008.150; PMID: 18846107
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vanden Berghe T, Vanlangenakker N, Buettner S, Eisenberg T, Vandenabeele P, et al. Programmed necrosis from molecules to health and disease. Int Rev Cell Mol Biol 2011; 289:1 - 35; http://dx.doi.org/10.1016/B978-0-12-386039-2.00001-8; PMID: 21749897
   PubMed Web of Science ®Google Scholar
• Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11:700 - 14; http://dx.doi.org/10.1038/nrm2970; PMID: 20823910
   PubMed Web of Science ®Google Scholar
• Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9:353 - 63; http://dx.doi.org/10.1038/nri2545; PMID: 19365408
   PubMed Web of Science ®Google Scholar
• Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691 - 701; http://dx.doi.org/10.1084/jem.20050915; PMID: 16365148
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010; 140:798 - 804; http://dx.doi.org/10.1016/j.cell.2010.02.015; PMID: 20303871
   PubMed Web of Science ®Google Scholar
• Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30:61 - 9; http://dx.doi.org/10.1007/s10555-011-9273-4; PMID: 21249425
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54 - 61; http://dx.doi.org/10.1038/nm1523; PMID: 17187072
   PubMed Web of Science ®Google Scholar
• Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008; 15:1499 - 509; http://dx.doi.org/10.1038/cdd.2008.67; PMID: 18464797
   PubMed Web of Science ®Google Scholar
• Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28:578 - 90; http://dx.doi.org/10.1038/emboj.2009.1; PMID: 19165151
   PubMed Web of Science ®Google Scholar
• Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71:4821 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-11-0950; PMID: 21602432
   PubMed Web of Science ®Google Scholar
• Zappasodi R, Pupa SM, Ghedini GC, Bongarzone I, Magni M, Cabras AD, et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 2010; 70:9062 - 72; http://dx.doi.org/10.1158/0008-5472.CAN-10-1825; PMID: 20884630
   PubMed Web of Science ®Google Scholar
• Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L, et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009; 8:3723 - 8; http://dx.doi.org/10.4161/cc.8.22.10026; PMID: 19855167
   PubMed Web of Science ®Google Scholar
• Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents. Science 2012; 334:1573 - 7; http://dx.doi.org/10.1126/science.1208347; PMID: 22174255
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170 - 8; http://dx.doi.org/10.1038/nm.2028; PMID: 19767732
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220:47 - 59; http://dx.doi.org/10.1111/j.1600-065X.2007.00573.x; PMID: 17979839
   PubMed Web of Science ®Google Scholar
• Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998; 4:581 - 7; http://dx.doi.org/10.1038/nm0598-581; PMID: 9585232
   PubMed Web of Science ®Google Scholar
• Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002; 2:185 - 94; http://dx.doi.org/10.1038/nri749; PMID: 11913069
   PubMed Web of Science ®Google Scholar
• Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2:63ra94; http://dx.doi.org/10.1126/scitranslmed.3001375; PMID: 21178137
   PubMed Web of Science ®Google Scholar
• Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461:282 - 6; http://dx.doi.org/10.1038/nature08296; PMID: 19741708
   PubMed Web of Science ®Google Scholar
• Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010; 70:855 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-09-3566; PMID: 20086177
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050 - 9; http://dx.doi.org/10.1038/nm1622; PMID: 17704786
   PubMed Web of Science ®Google Scholar
• Castellino F, Boucher PE, Eichelberg K, Mayhew M, Rothman JE, Houghton AN, et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 1999; 191:1957 - 64; http://dx.doi.org/10.1084/jem.191.11.1957; PMID: 10839810
   PubMed Web of Science ®Google Scholar
• Lee Y, Auh SL, Wang Y, Burnette B, Meng Y, Beckett M, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009; 114:589 - 95; http://dx.doi.org/10.1182/blood-2009-02-206870; PMID: 19349616
   PubMed Web of Science ®Google Scholar
• Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71:768 - 78; http://dx.doi.org/10.1158/0008-5472.CAN-10-2788; PMID: 21156650
   PubMed Web of Science ®Google Scholar
• Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29:482 - 91; http://dx.doi.org/10.1038/onc.2009.356; PMID: 19881547
   PubMed Web of Science ®Google Scholar
• Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30:1147 - 58; http://dx.doi.org/10.1038/onc.2010.500; PMID: 21151176
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Gressmann S, Becker S, Wittig S, Schmudde M, Beck JF. The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. Cancer Chemother Pharmacol 2010; 66:611 - 6; http://dx.doi.org/10.1007/s00280-010-1302-4; PMID: 20221600
   PubMed Web of Science ®Google Scholar
• Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008; 112:1424 - 33; http://dx.doi.org/10.1182/blood-2008-01-133769; PMID: 18541724
   PubMed Web of Science ®Google Scholar
• Lucas JL, Mirshahpanah P, Haas-Stapleton E, Asadullah K, Zollner TM, Numerof RP. Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell Immunol 2009; 257:97 - 104; http://dx.doi.org/10.1016/j.cellimm.2009.03.004; PMID: 19358983
   PubMed Web of Science ®Google Scholar
• Schmudde M, Friebe E, Sonnemann J, Beck JF, Broker BM. Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions. Cancer Lett 2010; 295:173 - 81; http://dx.doi.org/10.1016/j.canlet.2010.02.024; PMID: 20346580
   PubMed Web of Science ®Google Scholar
• Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009; 6:638 - 47; http://dx.doi.org/10.1038/nrclinonc.2009.146; PMID: 19786984
   PubMed Web of Science ®Google Scholar
• Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002; 8:142 - 54; http://dx.doi.org/10.1191/1352458502ms790oa; PMID: 11990872
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secrete ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; In press
   PubMed Web of Science ®Google Scholar
• Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, et al. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 2010; 115:4384 - 92; http://dx.doi.org/10.1182/blood-2009-11-251231; PMID: 20154220
   PubMed Web of Science ®Google Scholar
• Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010; 28:2874 - 80; http://dx.doi.org/10.1200/JCO.2009.24.7643; PMID: 20458045
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011; 12:460 - 8; http://dx.doi.org/10.1016/S1470-2045(11)70069-9; PMID: 21482186
   PubMed Web of Science ®Google Scholar
• Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, et al. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 2010; 28:77 - 82; http://dx.doi.org/10.1200/JCO.2009.22.1077; PMID: 19901117
   PubMed Web of Science ®Google Scholar
• Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010; 28:1863 - 9; http://dx.doi.org/10.1200/JCO.2009.25.9630; PMID: 20212251
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1756 - 65; http://dx.doi.org/10.1200/JCO.2009.26.4556; PMID: 20194844
   PubMed Web of Science ®Google Scholar
• Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol 2009; 27:5182 - 8; http://dx.doi.org/10.1200/JCO.2009.22.3768; PMID: 19770373
   PubMed Web of Science ®Google Scholar
• Beverly Raney R, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2011; 29:1312 - 8; http://dx.doi.org/10.1200/JCO.2010.30.4469; PMID: 21357783
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Friedman WH, Galon J, Sautès-Friedman C, Tartour E, et al. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunol 2012; 1:28 - 37
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641 - 8; http://dx.doi.org/10.1007/s00262-006-0225-8; PMID: 16960692
   PubMed Web of Science ®Google Scholar
• Greten TF, Ormandy LA, Fikuart A, Hochst B, Henschen S, Horning M, et al. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother 2010; 33:211 - 8; http://dx.doi.org/10.1097/CJI.0b013e3181bb499f; PMID: 20139774
   PubMed Web of Science ®Google Scholar
• Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007; 177:2136 - 40, discussion 40; http://dx.doi.org/10.1016/j.juro.2007.01.143; PMID: 17509300
   PubMed Web of Science ®Google Scholar
• Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 2011; In press http://dx.doi.org/10.1007/s00262-011-1081-8; PMID: 22021066
   PubMed Web of Science ®Google Scholar
• de Vries IJ, Castelli C, Huygens C, Jacobs JF, Stockis J, Schuler-Thurner B, et al. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res 2011; 17:841 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-10-2227; PMID: 21177412
   PubMed Web of Science ®Google Scholar
• Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011; 118:4853 - 62; http://dx.doi.org/10.1182/blood-2011-01-329656; PMID: 21908423
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr., Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 2011; 29:2924 - 32; http://dx.doi.org/10.1200/JCO.2010.33.8053; PMID: 21690475
   PubMed Web of Science ®Google Scholar
• Weiss RB. The anthracyclines: will we ever find a better doxorubicin?. Semin Oncol 1992; 19:670 - 86; PMID: 1462166
   PubMed Web of Science ®Google Scholar
• Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 1976; 36:2891 - 5; PMID: 1277199
   PubMed Web of Science ®Google Scholar
• Hayek ER, Speakman E, Rehmus E. Acute doxorubicin cardiotoxicity. N Engl J Med 2005; 352:2456 - 7; http://dx.doi.org/10.1056/NEJM200506093522321; PMID: 15944435
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2011; In press http://dx.doi.org/10.1038/onc.2011.384; PMID: 21892204
   PubMed Web of Science ®Google Scholar
• Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 2007; 120:175 - 80; http://dx.doi.org/10.1002/ijc.22132; PMID: 17044026
   PubMed Web of Science ®Google Scholar
• Gourdier I, Crabbe L, Andreau K, Pau B, Kroemer G. Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene 2004; 23:7449 - 57; http://dx.doi.org/10.1038/sj.onc.1208047; PMID: 15334062
   PubMed Web of Science ®Google Scholar
• Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L, et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008; 27:4221 - 32; http://dx.doi.org/10.1038/onc.2008.63; PMID: 18362892
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Morselli E, Kepp O, Tajeddine N, Kroemer G. Targeting p53 to mitochondria for cancer therapy. Cell Cycle 2008; 7:1949 - 55; http://dx.doi.org/10.4161/cc.7.13.6222; PMID: 18642442
   PubMed Web of Science ®Google Scholar
• Stordal B, Pavlakis N, Davey R. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat Rev 2007; 33:347 - 57; http://dx.doi.org/10.1016/j.ctrv.2007.01.009; PMID: 17383100
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011; 121:3100 - 8; http://dx.doi.org/10.1172/JCI43656; PMID: 21765211
   PubMed Web of Science ®Google Scholar
• Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011; 12:1032 - 44; http://dx.doi.org/10.1016/S1470-2045(11)70199-1; PMID: 21903473
   PubMed Web of Science ®Google Scholar
• Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E, Wolff RA, et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 2011; 29:1997 - 2003; http://dx.doi.org/10.1200/JCO.2010.29.4496; PMID: 21464406
   PubMed Web of Science ®Google Scholar
• Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104–a randomized trial of the German AIO CRC study group. J Clin Oncol 2011; 29:1050 - 8; http://dx.doi.org/10.1200/JCO.2010.31.1936; PMID: 21300933
   PubMed Web of Science ®Google Scholar
• Raez LE, Kobina S, Santos ES. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2010; 11:18 - 24; http://dx.doi.org/10.3816/CLC.2010.n.003; PMID: 20085863
   PubMed Web of Science ®Google Scholar
• Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011; 29:3037 - 43; http://dx.doi.org/10.1200/JCO.2010.33.8038; PMID: 21709185
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817 - 25; http://dx.doi.org/10.1056/NEJMoa1011923; PMID: 21561347
   PubMed Web of Science ®Google Scholar
• Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010; 11:48 - 54; http://dx.doi.org/10.1016/S1470-2045(09)70333-X; PMID: 19932054
   PubMed Web of Science ®Google Scholar
• Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010; 11:1142 - 8; http://dx.doi.org/10.1016/S1470-2045(10)70247-3; PMID: 21071270
   PubMed Web of Science ®Google Scholar
• Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 2009; 27:2598 - 603; http://dx.doi.org/10.1200/JCO.2008.19.7145; PMID: 19164203
   PubMed Web of Science ®Google Scholar
• Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010; 28:4581 - 6; http://dx.doi.org/10.1200/JCO.2010.29.3605; PMID: 20855823
   PubMed Web of Science ®Google Scholar
• Fox ME, Smith PJ. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res 1990; 50:5813 - 8; PMID: 2168281
   PubMed Web of Science ®Google Scholar
• Stuart-Harris R, Pearson M, Smith IE, Olsen EG. Cardiotoxicity associated with mitoxantrone. Lancet 1984; 324:219 - 20; http://dx.doi.org/10.1016/S0140-6736(84)90498-7; PMID: 6146768
   PubMed Web of Science ®Google Scholar
• Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther 2006; 28:461 - 74; http://dx.doi.org/10.1016/j.clinthera.2006.04.013; PMID: 16750460
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147 - 54; http://dx.doi.org/10.1016/S0140-6736(10)61389-X; PMID: 20888992
   PubMed Web of Science ®Google Scholar
• Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010; 376:2009 - 17; http://dx.doi.org/10.1016/S0140-6736(10)62002-8; PMID: 21131038
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol 2011; 33:335 - 40; http://dx.doi.org/10.1007/s00281-011-0264-x; PMID: 21461991
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960 - 4; http://dx.doi.org/10.1126/science.1129139; PMID: 17008531
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610 - 8; http://dx.doi.org/10.1200/JCO.2010.30.5425; PMID: 21245428
   PubMed Web of Science ®Google Scholar